Genmab A/S
CSE:GMAB
Genmab A/S
Total Receivables
Genmab A/S
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Total Receivables
kr6.7B
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
51%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Receivables
kr291m
|
CAGR 3-Years
38%
|
CAGR 5-Years
79%
|
CAGR 10-Years
24%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Receivables
€177.4m
|
CAGR 3-Years
97%
|
CAGR 5-Years
101%
|
CAGR 10-Years
54%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Receivables
kr1.2B
|
CAGR 3-Years
40%
|
CAGR 5-Years
78%
|
CAGR 10-Years
19%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Receivables
kr17.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Saniona AB
STO:SANION
|
Total Receivables
kr15m
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Total Receivables?
Total Receivables
6.7B
DKK
Based on the financial report for Dec 31, 2024, Genmab A/S's Total Receivables amounts to 6.7B DKK.
What is Genmab A/S's Total Receivables growth rate?
Total Receivables CAGR 10Y
51%
Over the last year, the Total Receivables growth was 35%. The average annual Total Receivables growth rates for Genmab A/S have been 25% over the past three years , 17% over the past five years , and 51% over the past ten years .
You don't have any saved screeners yet